2025-04-012026-03-312026-03-31false14307716OBK HEALTH LTD2026-08-11falseiso4217:GBPxbrli:pure143077162025-03-31143077162026-03-31143077162025-04-012026-03-31143077162024-03-31143077162025-03-31143077162024-04-012025-03-3114307716bus:SmallEntities2025-04-012026-03-3114307716bus:AuditExempt-NoAccountantsReport2025-04-012026-03-3114307716bus:FullAccounts2025-04-012026-03-3114307716bus:PrivateLimitedCompanyLtd2025-04-012026-03-3114307716core:WithinOneYear2026-03-3114307716core:AfterOneYear2026-03-3114307716core:WithinOneYear2025-03-3114307716core:AfterOneYear2025-03-3114307716core:ShareCapital2026-03-3114307716core:SharePremium2026-03-3114307716core:RevaluationReserve2026-03-3114307716core:OtherReservesSubtotal2026-03-3114307716core:RetainedEarningsAccumulatedLosses2026-03-3114307716core:ShareCapital2025-03-3114307716core:SharePremium2025-03-3114307716core:RevaluationReserve2025-03-3114307716core:OtherReservesSubtotal2025-03-3114307716core:RetainedEarningsAccumulatedLosses2025-03-3114307716core:LandBuildings2026-03-3114307716core:PlantMachinery2026-03-3114307716core:Vehicles2026-03-3114307716core:FurnitureFittings2026-03-3114307716core:OfficeEquipment2026-03-3114307716core:NetGoodwill2026-03-3114307716core:IntangibleAssetsOtherThanGoodwill2026-03-3114307716core:ListedExchangeTraded2026-03-3114307716core:UnlistedNon-exchangeTraded2026-03-3114307716core:LandBuildings2025-03-3114307716core:PlantMachinery2025-03-3114307716core:Vehicles2025-03-3114307716core:FurnitureFittings2025-03-3114307716core:OfficeEquipment2025-03-3114307716core:NetGoodwill2025-03-3114307716core:IntangibleAssetsOtherThanGoodwill2025-03-3114307716core:ListedExchangeTraded2025-03-3114307716core:UnlistedNon-exchangeTraded2025-03-3114307716core:LandBuildings2025-04-012026-03-3114307716core:PlantMachinery2025-04-012026-03-3114307716core:Vehicles2025-04-012026-03-3114307716core:FurnitureFittings2025-04-012026-03-3114307716core:OfficeEquipment2025-04-012026-03-3114307716core:NetGoodwill2025-04-012026-03-3114307716core:IntangibleAssetsOtherThanGoodwill2025-04-012026-03-3114307716core:ListedExchangeTraded2025-04-012026-03-3114307716core:UnlistedNon-exchangeTraded2025-04-012026-03-3114307716core:MoreThanFiveYears2025-04-012026-03-3114307716core:Non-currentFinancialInstruments2026-03-3114307716core:Non-currentFinancialInstruments2025-03-3114307716dpl:CostSales2025-04-012026-03-3114307716dpl:DistributionCosts2025-04-012026-03-3114307716core:LandBuildings2025-04-012026-03-3114307716core:PlantMachinery2025-04-012026-03-3114307716core:Vehicles2025-04-012026-03-3114307716core:FurnitureFittings2025-04-012026-03-3114307716core:OfficeEquipment2025-04-012026-03-3114307716dpl:AdministrativeExpenses2025-04-012026-03-3114307716core:NetGoodwill2025-04-012026-03-3114307716core:IntangibleAssetsOtherThanGoodwill2025-04-012026-03-3114307716dpl:GroupUndertakings2025-04-012026-03-3114307716dpl:ParticipatingInterests2025-04-012026-03-3114307716dpl:GroupUndertakingscore:ListedExchangeTraded2025-04-012026-03-3114307716core:ListedExchangeTraded2025-04-012026-03-3114307716dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-04-012026-03-3114307716core:UnlistedNon-exchangeTraded2025-04-012026-03-3114307716dpl:CostSales2024-04-012025-03-3114307716dpl:DistributionCosts2024-04-012025-03-3114307716core:LandBuildings2024-04-012025-03-3114307716core:PlantMachinery2024-04-012025-03-3114307716core:Vehicles2024-04-012025-03-3114307716core:FurnitureFittings2024-04-012025-03-3114307716core:OfficeEquipment2024-04-012025-03-3114307716dpl:AdministrativeExpenses2024-04-012025-03-3114307716core:NetGoodwill2024-04-012025-03-3114307716core:IntangibleAssetsOtherThanGoodwill2024-04-012025-03-3114307716dpl:GroupUndertakings2024-04-012025-03-3114307716dpl:ParticipatingInterests2024-04-012025-03-3114307716dpl:GroupUndertakingscore:ListedExchangeTraded2024-04-012025-03-3114307716core:ListedExchangeTraded2024-04-012025-03-3114307716dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-04-012025-03-3114307716core:UnlistedNon-exchangeTraded2024-04-012025-03-3114307716core:NetGoodwill2026-03-3114307716core:IntangibleAssetsOtherThanGoodwill2026-03-3114307716core:LandBuildings2026-03-3114307716core:PlantMachinery2026-03-3114307716core:Vehicles2026-03-3114307716core:FurnitureFittings2026-03-3114307716core:OfficeEquipment2026-03-3114307716core:AfterOneYear2026-03-3114307716core:WithinOneYear2026-03-3114307716core:ListedExchangeTraded2026-03-3114307716core:UnlistedNon-exchangeTraded2026-03-3114307716core:ShareCapital2026-03-3114307716core:SharePremium2026-03-3114307716core:RevaluationReserve2026-03-3114307716core:OtherReservesSubtotal2026-03-3114307716core:RetainedEarningsAccumulatedLosses2026-03-3114307716core:NetGoodwill2025-03-3114307716core:IntangibleAssetsOtherThanGoodwill2025-03-3114307716core:LandBuildings2025-03-3114307716core:PlantMachinery2025-03-3114307716core:Vehicles2025-03-3114307716core:FurnitureFittings2025-03-3114307716core:OfficeEquipment2025-03-3114307716core:AfterOneYear2025-03-3114307716core:WithinOneYear2025-03-3114307716core:ListedExchangeTraded2025-03-3114307716core:UnlistedNon-exchangeTraded2025-03-3114307716core:ShareCapital2025-03-3114307716core:SharePremium2025-03-3114307716core:RevaluationReserve2025-03-3114307716core:OtherReservesSubtotal2025-03-3114307716core:RetainedEarningsAccumulatedLosses2025-03-3114307716core:NetGoodwill2024-03-3114307716core:IntangibleAssetsOtherThanGoodwill2024-03-3114307716core:LandBuildings2024-03-3114307716core:PlantMachinery2024-03-3114307716core:Vehicles2024-03-3114307716core:FurnitureFittings2024-03-3114307716core:OfficeEquipment2024-03-3114307716core:AfterOneYear2024-03-3114307716core:WithinOneYear2024-03-3114307716core:ListedExchangeTraded2024-03-3114307716core:UnlistedNon-exchangeTraded2024-03-3114307716core:ShareCapital2024-03-3114307716core:SharePremium2024-03-3114307716core:RevaluationReserve2024-03-3114307716core:OtherReservesSubtotal2024-03-3114307716core:RetainedEarningsAccumulatedLosses2024-03-3114307716core:AfterOneYear2025-04-012026-03-3114307716core:WithinOneYear2025-04-012026-03-3114307716core:Non-currentFinancialInstrumentscore:CostValuation2025-04-012026-03-3114307716core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-04-012026-03-3114307716core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-04-012026-03-3114307716core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-04-012026-03-3114307716core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-04-012026-03-3114307716core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-04-012026-03-3114307716core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-04-012026-03-3114307716core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-04-012026-03-3114307716core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-04-012026-03-3114307716core:Non-currentFinancialInstrumentscore:CostValuation2026-03-3114307716core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-03-3114307716core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-03-3114307716core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-03-3114307716core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-03-3114307716core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-03-3114307716core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2026-03-3114307716core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-03-3114307716core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-03-3114307716core:Non-currentFinancialInstrumentscore:CostValuation2025-03-3114307716core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-03-3114307716core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-03-3114307716core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-03-3114307716core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-03-3114307716core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-03-3114307716core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-03-3114307716core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-03-3114307716core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-03-3114307716bus:Director12025-04-012026-03-3114307716bus:Director22025-04-012026-03-31

OBK HEALTH LTD

Registered Number
14307716
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2026

OBK HEALTH LTD
Company Information
for the year from 1 April 2025 to 31 March 2026

Directors

BAKARE-KENNETT, Oluwadamilola, Dr
BAKARE-KENNETT, Sophie

Registered Address

Fulford Lodge 1 Heslington Lane
Fulford
York
YO10 4HW

Registered Number

14307716 (England and Wales)
OBK HEALTH LTD
Statement of Financial Position
31 March 2026

Notes

2026

2025

£

£

£

£

Fixed assets
Tangible assets351,3701,706
51,3701,706
Current assets
Debtors15,36223,439
Cash at bank and on hand66,46935,583
81,83159,022
Creditors amounts falling due within one year4(29,402)(23,266)
Net current assets (liabilities)52,42935,756
Total assets less current liabilities103,79937,462
Creditors amounts falling due after one year5(48,704)-
Net assets55,09537,462
Capital and reserves
Called up share capital100100
Profit and loss account54,99537,362
Shareholders' funds55,09537,462
The financial statements were approved and authorised for issue by the Board of Directors on 11 August 2026, and are signed on its behalf by:
BAKARE-KENNETT, Oluwadamilola, Dr
Director
Registered Company No. 14307716
OBK HEALTH LTD
Notes to the Financial Statements
for the year ended 31 March 2026

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 Section 1A, The Financial Reporting Standard applicable in the UK and Republic of Ireland.
Basis of preparation
The financial statements have been prepared on the historical cost basis.
Functional and presentation currency
The financial statements are presented in sterling, which is the functional currency of the entity.
Going concern
The UK economy has recently been impacted by rising inflation, interest rates and energy costs, exacerbated by the war in Ukraine. All these matters have impacted the company's trading results to a greater or lesser extent. At the date of signing these financial statements, the directors have considered the effect of these matters on the company with the information available to it and do not believe that it will affect the ability of the company to continue to trade for the foreseeable future. On this basis, the directors have prepared these financial statements on a going concern basis.
Revenue from sale of goods
The revenue shown in the profit and loss account represents income receivable from dental treatments carried out during the period. Revenue in respect of dental treatment uncompleted at the year end date is recognised by reference to the state of completion.
Employee benefits
Contributions to defined contribution plans are expensed in the period to which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.
Current taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amount of tax expected to pay or recover using the tax rates and laws that have been enacted, or substantively enacted, at the reporting date.
Tangible fixed assets and depreciation
Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses. Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:
2.Average number of employees

20262025
Average number of employees during the year01
3.Tangible fixed assets

Plant & machinery

Vehicles

Office Equipment

Total

££££
Cost or valuation
At 01 April 252,510--2,510
Additions9,38955,1402,25866,787
At 31 March 2611,89955,1402,25869,297
Depreciation and impairment
At 01 April 25804--804
Charge for year2,77313,78556517,123
At 31 March 263,57713,78556517,927
Net book value
At 31 March 268,32241,3551,69351,370
At 31 March 251,706--1,706
4.Creditors: amounts due within one year

2026

2025

££
Trade creditors / trade payables677870
Amounts owed to related parties1,1702,584
Taxation and social security26,35518,611
Accrued liabilities and deferred income1,2001,201
Total29,40223,266
5.Creditors: amounts due after one year

2026

2025

££
Bank borrowings and overdrafts48,704-
Total48,704-
6.Related party transactions
During the year the directors made available a loan to the company. At the year end the balance of the loan was £1,169 (2025: £2,583).